Thursday 19 November 2026 Sign in / SubscribeFree daily emailMarket analysisEnterprise solutionsVigiEye regulatory newsCompePharma CRM & HR →
The business of pharma
CP+ Earnings analysis
Harrow, Inc. · HROW · Third quarter 2026

Harrow's record Q3 revenue meets a halved EBITDA outlook, as Q4 must carry the year

Branded sales drove 39% year-over-year growth, but Harrow cut full-year Adjusted EBITDA guidance to more than $40 million and now needs a steep fourth quarter to hit revenue targets.

17 Nov 2026 · CompePharma editorial
$99.3 millionQ3 2026 total revenue
$83.5 million, up 62%Branded revenue (YoY growth)
$21.2 millionQ3 Adjusted EBITDA
more than $40 millionFY2026 Adjusted EBITDA guidance (prior: $80M-$100M)
$350 million to $365 millionFY2026 revenue guidance (reaffirmed)
$75.3 millionCash and cash equivalents, Sept. 30, 2026

The quarter in numbers

Harrow reported record third-quarter revenue of $99.3 million, up 41% sequentially and 39% from $71.6 million a year earlier. Branded products brought in $83.5 million, up 62% year over year and about 84% of the total.

Gross margin was 75%, unchanged from the third quarter of 2025. GAAP net income was $9.8 million ($0.25 per diluted share), against a $1.0 million profit a year ago and a $17.3 million net loss in the second quarter of 2026. The company said the quarter included a $5.0 million litigation settlement gain.

Adjusted EBITDA, a non-GAAP measure, was $21.2 million. That is a sharp recovery from $(1.2) million in the second quarter but slightly below the $22.8 million of the third quarter of 2025.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on CompePharma and VigiEye
  • One subscription for both sites, cancel any time
Continue with Google
or
You'll be signed in straight away; we also email you a link to confirm your address. Reading every article takes a $4.99/month subscription (secure checkout by Stripe), billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. See our terms and privacy policy.

Sources

Written by CompePharma's editorial system (AI-assisted, model claude-sonnet-5-5) strictly from the official material listed. Earnings analysis is based on the company's results release filed with the SEC, not on the earnings call. It can contain errors; check the sources. Not investment advice.

More CP+ Earnings analysisAll →
CP+ Earnings analysis
Tonix Pharmaceuticals Holding Corp. · TNXP · Third quarter 2026

Tonix's TONMYA reaches $15M, but a $163M cash pile and a Paragraph IV filing frame the debate

approximately $17.2 million (vs $3.3 million in Q3 2025)Net product revenue, Q3 2026approximately $15.0 million, up 37% from Q2TONMYA net sales, Q3 2026$53.3 million, or $2.89 per shareNet loss to common, Q3 2026

Third-quarter net product revenue rose to about $17.2M, yet opex of $72.7M and a runway only into early Q3 2027 mean financing and patent litigation loom over the launch.

19 Nov 2026 · CompePharma editorial
CP+ Earnings analysis
ADC Therapeutics SA · ADCT · Third quarter 2026

ADC Therapeutics: volume-led sales and deeper cost cuts, as recapitalisation shifts focus to ASH

$21.0 million (vs $15.8 million in Q3 2025)Q3 2026 net product revenue$36.1 million, a 24% reductionQ3 total operating expenses$25.3 million, or $0.16 per share (vs $41.0 million, or $0.30)Q3 net loss

Q3 net product revenue of $21.0M and a 29% cut in adjusted opex narrowed the loss, while an October restructuring extended the company's expected cash runway into 2029.

18 Nov 2026 · CompePharma editorial
CP+ Earnings analysis
Inhibrx Biosciences, Inc. · INBX · Third quarter 2026

Inhibrx's Q3: Debt and launch prep push losses up as chondrosarcoma review looms

$2.0 millionQ3 2026 revenue$38.7 million, or $2.46 per shareQ3 2026 net loss$26.0 million vs $28.5 million in Q3 2025Q3 R&D expense

A $2.0 million Pfizer licence fee barely dented a $38.7 million net loss as interest costs and pre-commercial spend rose while R&D fell and the balance sheet moved into deficit.

18 Nov 2026 · CompePharma editorial